Scarica l'app Stockscreener
16.78
2.75%
0.39
Precedente Chiudi:
$16.39
Aprire:
$16.39
Volume 24 ore:
473.89K
Relative Volume:
2.20
Capitalizzazione di mercato:
$558.90M
Reddito:
$65.42M
Utile/perdita netta:
$-32.96M
Rapporto P/E:
-13.21
EPS:
-1.27
Flusso di cassa netto:
$-19.87M
1 W Prestazione:
+9.07%
1M Prestazione:
+2.68%
6M Prestazione:
+64.77%
1 anno Prestazione:
+35.59%
Intervallo 1D:
$16.22
$17.39
Intervallo di 1 settimana:
$15.03
$17.39
Portata 52W:
$7.5625
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Nome
Neuropace Inc
Settore
Industria
Telefono
(650) 237-2700
Indirizzo
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Confronta NPCE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
16.78 | 545.91M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
127.03 | 222.19B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.64 | 144.97B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.64 | 140.12B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.78 | 128.60B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.58 | 49.82B | 5.88B | 1.34B | 799.60M | 2.3489 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-28 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-21 | Iniziato | UBS | Buy |
| 2024-03-14 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Iniziato | Leerink Partners | Outperform |
| 2023-11-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Iniziato | Lake Street | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Iniziato | Robert W. Baird | Outperform |
| 2021-05-17 | Iniziato | JP Morgan | Overweight |
| 2021-05-17 | Iniziato | Morgan Stanley | Overweight |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-17 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Neuropace Inc Borsa (NPCE) Ultime notizie
Why NeuroPace Inc. stock remains undervalued2026 world cup usa national team round of 16 defensive leaders pressing system knockout prediction breakdown - ulpravda.ru
NeuroPace (NASDAQ:NPCE) Sees Strong Trading VolumeHere's Why - MarketBeat
UBS sees upside for NeuroPace shares with 22% CAGR and market expansion drivers - MSN
Responsive Playbooks and the NPCE Inflection - Stock Traders Daily
FOMO Trade: Is NeuroPace Inc stock oversold or undervalued2025 Pullback Review & Low Risk High Win Rate Picks - moha.gov.vn
NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
Is NeuroPace Inc. stock a buy on dipsPrice Momentum Alerts & Grow Steadily With Our Wealth Roadmap - bollywoodhelpline.com
Published on: 2025-12-25 19:47:27 - moha.gov.vn
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Liquidity Mapping Around (NPCE) Price Events - Stock Traders Daily
How resilient is NeuroPace Inc. stock in market downturns2025 Market WrapUp & Long Hold Capital Preservation Tips - bolumsonucanavari.com
Reviewing NeuroPace (NASDAQ:NPCE) & PROCEPT BioRobotics (NASDAQ:PRCT) - Defense World
Why NeuroPace Inc. stock attracts global investorsInflation Watch & Weekly Watchlist for Hot Stocks - Улправда
How NeuroPace Inc. stock performs in rate cut cycles2025 Earnings Impact & Weekly Watchlist for Consistent Profits - DonanımHaber
Is NeuroPace Inc. stock attractive for growth ETFs2025 Buyback Activity & Risk Controlled Daily Plans - Улправда
Can NeuroPace Inc. stock deliver sustainable ROEWatch List & Fast Entry and Exit Trade Plans - Улправда
Is NeuroPace Inc. stock oversold or undervaluedTrade Exit Report & Expert Curated Trade Ideas - DonanımHaber
Will NeuroPace Inc. stock outperform growth indexes2025 Volume Leaders & Stepwise Entry and Exit Trade Signals - Улправда
Will NeuroPace Inc. stock benefit from green energy trendsWeekly Trade Report & Entry and Exit Point Strategies - DonanımHaber
Aug Rallies: Can NeuroPace Inc. stock deliver sustainable ROETrade Performance Summary & Weekly High Conviction Trade Ideas - ulpravda.ru
Lake Street Keeps Their Buy Rating on NeuroPace (NPCE) - The Globe and Mail
UBS Group Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price - Defense World
NeuroPace seeks FDA approval to expand RNS System for epilepsy treatment - Investing.com Nigeria
Is It Time To Consider Buying NeuroPace, Inc. (NASDAQ:NPCE)? - Yahoo Finance
NeuroPace Files FDA Application to Expand RNS System Use - marketscreener.com
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy - Investing News Network
Neuropace files PMA supplement to FDA - marketscreener.com
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS - Business Wire
UBS Maintains NeuroPace (NPCE) Buy Recommendation - Nasdaq
UBS Adjusts NeuroPace Price Target to $22 From $18, Maintains Buy Rating - marketscreener.com
UBS Group Raises NeuroPace (NASDAQ:NPCE) Price Target to $22.00 - MarketBeat
Wells Fargo Sticks to Their Buy Rating for NeuroPace (NPCE) - The Globe and Mail
NeuroPace (NASDAQ:NPCE) Price Target Raised to $20.00 at JPMorgan Chase & Co. - Defense World
NeuroPace price target raised to $20 from $18 at JPMorgan - MSN
Bank Watch: How buybacks impact NeuroPace Inc stock value2025 Biggest Moves & AI Forecast Swing Trade Picks - moha.gov.vn
JP Morgan Raises Price Target for NPCE to $20.00, Maintains Over - GuruFocus
JPMorgan Chase & Co. Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price - MarketBeat
NeuroPace presents NAUTILUS trial data at American Epilepsy Society meeting - MSN
NeuroPace stock rises on positive NAUTILUS trial results, UBS reiterates Buy - Investing.com UK
NeuroPace stock rises on positive NAUTILUS trial results, UBS reiterates Buy By Investing.com - Investing.com South Africa
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy - BioSpace
Neuropace shows 77% reduction in seizures - BioWorld MedTech
NeuroPace reports 77% seizure reduction in epilepsy device trial - Investing.com
NeuroPace reports 77% seizure reduction in epilepsy device trial By Investing.com - Investing.com Canada
Neuropace announces positive 18-month NAUTILUS trial results in idiopathic generalized epilepsy - marketscreener.com
NeuroPace, Inc. $NPCE Shares Acquired by Divisadero Street Capital Management LP - MarketBeat
Is NeuroPace Stock Built to Withstand a Pullback? - Trefis
MACD Signal: Will USCF ETF Trust USCF Sustainable stock attract long term capital inflowsJuly 2025 Analyst Calls & Reliable Intraday Trade Plans - BỘ NỘI VỤ
NeuroPace Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Panagora Asset Management Inc. Makes New $1.11 Million Investment in NeuroPace, Inc. $NPCE - MarketBeat
Will NeuroPace Inc. stock deliver consistent dividendsEarnings Growth Summary & Reliable Price Breakout Signals - Newser
Neuropace Inc Azioni (NPCE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Neuropace Inc Azioni (NPCE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
May 14 '25 |
Sale |
15.85 |
168,136 |
2,665,333 |
3,238,199 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Feb 21 '25 |
Sale |
13.72 |
78,334 |
1,074,844 |
81,993 |
| KCK LTD. | 10% Owner |
Feb 20 '25 |
Sale |
9.40 |
5,270,845 |
49,545,943 |
0 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 30 '25 |
Sale |
15.00 |
200 |
3,000 |
86,762 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 29 '25 |
Sale |
15.00 |
100 |
1,500 |
86,962 |
1.20%
0.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):